Sunovion Pharmaceuticals, born from the merging of Dainippon Sumitomo Pharma America, Incorporated (DSPA), and Sepracor, Incorporated, develops treatments for patients suffering from respiratory issues and central nervous system disorders. It is constantly developing new approaches, such as the drug LUNESTA (eszopiclone), which promotes healthy sleeping patterns, and Latuda (lurasidone HCI) for patients with symptoms of schizophrenia. The company’s devotion to nervous system issues is timely. For instance, the World Health Organization ranks schizophrenia as the sixth largest cause of disabilities globally.
2. Sunovion Pharmaceuticals
Sunovion Pharmaceuticals, born from the merging of
Dainippon Sumitomo Pharma America, Incorporated
(DSPA), and Sepracor, Incorporated, develops
treatments for patients suffering from respiratory
issues and central nervous system disorders. It is
constantly developing new approaches, such as the
drug LUNESTA (eszopiclone), which promotes
healthy sleeping patterns, and Latuda (lurasidone
HCI) for patients with symptoms of schizophrenia.
The company’s devotion to nervous system issues is
timely. For instance, the World Health Organization
ranks schizophrenia as the sixth largest cause of
disabilities globally.
3. Sunovion Pharmaceuticals
Sunovion remains committed to developing new
products, and current research includes treatments for
bipolar disorder, overactive bladder, neuropathic
pain, major depressive disorder, diabetes, and
Alzheimer’s disease. Research findings are frequently
published in peer-reviewed journals, including the
Journal of Allergy and Clinical Immunology.
Material is also regularly presented at meetings of
organizations such as the National Medical
Association and the American Thoracic Society.
4. Sunovion Pharmaceuticals
Engel Burns is Sunovion Pharmaceuticals’
Federal Account Director of Government
Affairs. He was recently profiled in Ebony
Magazine for his achievements in this
position.